Biopharmaceutical Company
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities. HR 4302   Protecting Access to Medicare Act of 2014 - Public Law No: 113-93
In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs FY 2014 Omnibus HR 3547
FY 2014 Continuing Resolution H J Res 106 PL 113-73
FY 2014 Continuing Resolution H J Res 59 PL 113-67 
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation
HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
SLC HEALTH STRATEGIES, LLC
9710 Traville Gateway Drive, Number 157, Rockville, MD, 20850, US
SHARON COHEN SHARON COHEN SHARON COHEN SHARON COHEN